Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue.
Vedanta Biosciences Inc. has been awarded $3.9 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its VE-707 preclinical development program for reducing colonization and preventing subsequent infections caused by multidrug-resistant organisms (MRDOs).
Current approved antifungal therapies are limited by their associated adverse events. SCY-247 is a new triterpenoid antifungal for intravenous or oral administration that inhibits the glucan synthase enzyme, which is a key member for the fungal cell wall.
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease that results from an infection with the SFTS virus, with a case fatality rate of 6.1% to 21.8%. Identifying critically ill patients at the early stages is crucial for clinical management.
Researchers from State University of New Jersey (Rutgers) and Oklahoma State University have published preclinical data for a novel a SARS-CoV-2 papain-like protease (PLpro) inhibitor being developed as an antiviral candidate for the treatment of COVID-19.
Work at Duke University has led to the discovery of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors potentially useful for the treatment of cancer and gram-negative bacterial infections.
The administration of a cross-reactive monoclonal antibody (MAb) protected hamsters and African green monkeys (AGM) several days after Nipah virus (NiV) infection.
Researchers from Longhorn Vaccines & Diagnostics LLC have presented data at the ongoing ESCMID conference regarding their unconjugated multiepitope vaccine against influenza, LHNVD-105.
About 25% of subjects with West Nile virus (WNV) infection develop fever and about 1% have neuroinvasive disease. Recent research has proposed measuring CD169 in peripheral blood (monocyte/lymphocyte ratio) as a marker of viral infections. The usefulness of monocyte CD169 (mCD169) in peripheral blood was tested in subjects with active WNV infection.